Ireland
--:--IST
Recruiting Not applicable

Impact of Nipple Reconstruction in Mastectomized Patients Using Cross-Linked Hyaluronic Acid Injection.

NCT07008339 · tracked via the Priya Life Science Spain tracker
Phase
Not applicable
Started
2023-06-02
Last updated
2025-06-06

Condition(s) studied

Breast NeoplasmsMastectomyMammaplastyNipple DisorderTattooingHyaluronic AcidDermal FillersReconstructive Surgical ProceduresQuality of LifeSelf ConceptBody ImagePatient SatisfactionBreast ReconstructionNipple Reconstruction

Investigational drug(s) / intervention(s)

Areola MicropigmentationHyaluronic Acid Filler Injection

Areola Micropigmentation: Areola micropigmentation performed by trained nurses

Hyaluronic Acid Filler Injection: Subcutaneous injection of cross-linked hyaluronic acid filler (Juvederm®) for nipple projection.

Study summary

This study evaluates the impact of hyaluronic acid (HA) injection for nipple projection following mastectomy, as a complement to areola micropigmentation. While micropigmentation is standard in nipple-areola complex (NAC) reconstruction, HA use remains novel, with limited data on psychosocial, sexual, and aesthetic outcomes.

A sequential explanatory mixed-methods design will be used. In Phase 1, a randomized controlled trial will compare two groups: one receiving NAC micropigmentation alone (control) and the other receiving micropigmentation plus HA-based nipple projection (intervention). A total of 138 participants will be recruited at the Areolar Micropigmentation Unit of Germans Trias i Pujol University Hospital (Barcelona) over 36 months. Outcomes will include psychosocial and sexual well-being, satisfaction with breast and nipple appearance, and nipple projection, measured using the Spanish BREAST-Q, a custom satisfaction tool, and calipers.

Phase 2 will involve a qualitative phenomenological study using semi-structured interviews with a purposive sample from the intervention group. Thematic analysis will explore body image, emotional and social well-being, and overall satisfaction, using NVivo software.

This is the first study assessing HA nipple reconstruction by advanced practice nurses using validated patient-reported outcomes. While the BREAST-Q is appropriate, it may not fully capture emotional nuances, justifying qualitative exploration. HA durability is estimated at 6-9 months, but residual volume and satisfaction over time remain underexplored. HA's aesthetic footprint may allow reduced dosages in future applications.

This minimally invasive technique may reduce the need for surgical nipple reconstruction. Conducting the procedure in a nurse-led setting is novel and may enhance patient-centered care and the role of nursing in post-mastectomy recovery.

The study complies with the Declaration of Helsinki and Spanish biomedical regulations. Ethical approval was obtained. Participants will provide informed consent, and data will be anonymized and securely stored.

Eligibility

Sex
FEMALE
Min age
18 Years
Max age
—
Healthy volunteers
No
* Quantitative Phase * Inclusion Criteria: Women over 18 years of age, or with parental or legal guardian consent. At least one of the following criteria: Women undergoing their first nipple-areola complex (NAC) reconstruction through micropigmentation and/or: No previous neo-nipple surgery, either unilaterally or bilaterally. Surgical reconstruction of the areola. Surgical reconstruction of the NAC with subsequent retraction of the neo-nipple. More than 6 months since their last surgery. \- Exclusion Criteria: Allergy to hyaluronic acid. Poor tolerance to needle injections. Withdrawal Criteria: Participant's voluntary decision. Complications associated with the technique (allergy, hematoma, etc.). Clinical deterioration preventing the woman from continuing in the study. \- Qualitative Phase Participant Profile Characteristics: For the qualitative phase, women who have received NAC reconstruction with HA will be invited to participate, following the maximum variation criterion. To ensure the inclusion of participants with diverse characteristics and capture a wide range of perspectives and experiences on the phenomenon under study, women of varying ages, with different breast cancer diagnoses, and histories of various oncological, surgical, and therapeutic treatments will be selected.

Primary outcome measure(s)

  • Satisfaction with Nipple Reconstruction — 3, and 6 months after final injection session
    Patient-reported satisfaction with nipple reconstruction, measured using the "Satisfaction with Nipple" scale of the Spanish version of the BREAST-Q questionnaire. This scale ranges from 0 to 100, with higher scores indicating greater satisfaction."

Trial sites (1)

FacilityCityRegionStatus
Hospital Universitario Germans Trias i Pujol Badalona Barcelona Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07008339 on ClinicalTrials.gov ↗ ← All trials in Spain